EOM 1352: Fri 7 June 2024, 11:36
Media Pack
News

Current Edition

Volume 17 Issue 2
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Regional News

‘No small feat’: Albireo CEO talks biotech’s commercial transition amid Bylvay launch

Established in Sweden as a small spinout of AstraZeneca in 2008, Albireo always had big ambitions. After all, it was named after the striking “double star” in the Cyg...
23 March 2022 Regional News Albireo | AstraZeneca
Continue Reading →
Regional News

AstraZeneca and other lung cancer specialists join together to emphasize early screenings

If there is one strong message Camille Hertzka, AstraZeneca vice president and head of oncology, U.S. medical, wants people to take away from lung cancer awareness su...
15 December 2021 Regional News AstraZeneca | Guardant Health
Continue Reading →
Regional News

AstraZeneca’s Evusheld becomes first FDA-authorized COVID antibody to protect the immunocompromised before exposure

People in the U.S. with conditions that prevent them from building immunity with COVID-19 vaccines will soon have a way to get adequate protection from the virus. Wi...
10 December 2021 Regional News AstraZeneca | COVID
Continue Reading →
Regional News

Watch out, Pfizer and Alnylam. AstraZeneca wades deeper into rare diseases with Ionis tie-up

Just months after wrapping up the Alexion acquisition, AstraZeneca is beefing up its newly established rare disease portfolio with a collaboration with Ionis Pharmace...
8 December 2021 Regional News Alnylam Pharmaceuticals | AstraZeneca
Continue Reading →
Regional News

AstraZeneca CEO questions mRNA vaccine superiority, raising theory that his company’s shot offers longer-lasting protection

AstraZeneca’s chief executive Pascal Soriot is challenging the notion that his company's vaccine is inferior to the mRNA vaccines from Moderna and Pfizer. In fact, h...
24 November 2021 Regional News AstraZeneca | BioNTech
Continue Reading →
Regional News

J&J’s Invokana chases AZ’s Farxiga and Lilly’s Jardiance with phase 3 heart failure win

Chasing rivals from AstraZeneca and Eli Lilly/Boehringer Ingelheim, Johnson & Johnson's Invokana is vying for a piece of the lucrative heart failure market. J&am...
17 November 2021 Regional News AstraZeneca | Eli Lilly
Continue Reading →
Regional News

AstraZeneca resumes asset sale in $270M COPD deal with familiar buyer Covis

Over the years, AstraZeneca has consistently adjusted its portfolio, targeting aging products. The company has now found a new home for two respiratory meds with an o...
2 November 2021 Regional News AstraZeneca | clinical trial
Continue Reading →
Regional News

AstraZeneca strikes COVID-19 vaccine delivery deal with Europe, ending high-profile legal battle

At times during the pandemic, there’s been no love lost between AstraZeneca and the EU. After the U.K. pharma giant fell behind on its planned COVID-19 vaccine deliv...
8 September 2021 Regional News AstraZeneca | COVID-19
Continue Reading →
Regional News

AstraZeneca, Daiichi Sankyo build Enhertu’s blockbuster case with breast cancer win against Roche’s Kadcyla

AstraZeneca and Daiichi Sankyo’s Enhertu is shouldering big expectations. With a new head-to-head trial win against Roche’s Kadcyla, the companies are showing their a...
10 August 2021 Regional News AstraZeneca | Daiichi Sankyo’s Enhertu
Continue Reading →
Europe

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results. AstraZeneca and Eli Lilly’s lanabecesta...
13 June 2018 Europe 3 | Alzheimer
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2025, All Rights Reserved – Powered by Teksyte